ATLAS News · Companies

Merck signs cancer research deal with AI drug discovery firm Isomorphic Labs

· 1 sources

Seeking Alpha reports that Merck has agreed a cancer research deal with Isomorphic Labs, a company focused on AI-based drug discovery.

What happened

Seeking Alpha reports that Merck has entered into a cancer research agreement with Isomorphic Labs, a firm that uses artificial intelligence in drug discovery.

The source describes the arrangement as a deal centered on cancer research. The headline does not provide financial terms, timelines or the specific programs involved.

Context

Large pharmaceutical companies often work with technology firms that apply artificial intelligence to the search for new drug candidates.

Why it matters

The agreement shows how Merck is drawing on AI-focused partners in its oncology research, which investors following the company may watch.

Stocks in this story

Price changes are shown for the trading day of the story and are a coincidence in time, not proof that the news caused them. Figures are ATLAS data from our database.

Merck & Co.MRK

−3.90%

Healthcare · NYSE

Live price
$137.78

live price · USD

Latest close before this story
$137.78−3.90% vs. previous close ($143.37) · November 18
Fair value (ATLAS)
$61.72Fair range: $47.12 to $115.85The price ($137.78) is 123.3% above that figure.
Chance of a rise in 1 month
51%Probability of closing higher than today within 21 sessions.Normal range: half of the scenarios end between $130.94 and $145.54; 9 in 10, between $119.23 and $159.83.
See the full ATLAS analysis of Merck & Co. →

Closing prices, fair value and probabilities: ATLAS own data. How we calculate fair value.

Sources

ATLAS writes its own summaries from the reporting of these outlets. Each link opens the original publisher.

  1. Merck inks cancer research deal with AI drug discovery firm Isomorphic Labs · Seeking Alpha · November 19, 2026

Related

Latest market news · Markets today on ATLAS · Merck & Co.

What you get with ATLAS

Create my ATLAS account →

Fair value, probabilities and earnings for every stock. Free account, no card. Information, not advice.

Information, not advice. This content is informational and is not an investment recommendation or an offer to buy or sell securities. ATLAS estimates come from statistical models using public data, can be wrong, and past performance does not guarantee future results. Disclaimer

ATLAS Signals

ATLAS Signals, every week

The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.

By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy